Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

14.1K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.1K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

77.6K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
77.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of glutamine metabolism and ASCT2/SLC1A5 transporter on insulin resistance and endoplasmic reticulum stress in 3T3-L1 adipocytes.

Cytotechnology·2025
Same author

The effects of KIR2DL4 stimulated NK-92 cells on the apoptotic pathways of HER2 + /HER-breast cancer cells.

Medical oncology (Northwood, London, England)·2023
Same author

An in vitro Approach to Protective Effect of Lactoferrin on Acrylamide-induced Oxidative Damage.

Anais da Academia Brasileira de Ciencias·2022
See all related articles

Related Experiment Video

Updated: Jun 13, 2025

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.2K

Developing a novel neutralizing monoclonal antibody against TrkB.

Gamze Eda Yildirim1, Erkan Yilmaz1

  • 1Biotechnology Institute, Ankara University, Ankara, Türkiye.

3 Biotech
|September 9, 2024
PubMed
Summary

New monoclonal antibodies targeting the TrkB receptor show significant anti-cancer effects. The TrkB-IgL 5.11 antibody inhibits cancer cell proliferation and induces apoptosis, offering a promising therapeutic candidate for TrkB-overexpressing cancers.

Keywords:
Monoclonal antibodyNeutralizing antibodyTrkB

More Related Videos

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

7.7K
A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
10:44

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

7.2K

Related Experiment Videos

Last Updated: Jun 13, 2025

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.2K
Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

7.7K
A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
10:44

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

7.2K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • The TrkB receptor is highly expressed in human cancers and acts as a pro-oncogene.
  • Targeting TrkB is a strategy for developing novel cancer therapies.

Purpose of the Study:

  • To develop neutralizing monoclonal antibodies (mAbs) against the immunoglobulin-like (Ig-like) domains of the TrkB receptor.
  • To evaluate the anti-cancer efficacy of these novel antibodies.

Main Methods:

  • Recombinant TrkB-IgL peptide was expressed and purified.
  • Mice were immunized to generate hybridoma clones producing anti-TrkB-IgL antibodies.
  • Antibody efficacy was assessed via cell proliferation assays (xCELLigence) and Western blotting on cancer cell lines (MCF-7, HCT116) and SH-SY5Y cells.

Main Results:

  • Four hybridoma clones (TrkB-IgL 5.11, 4.11, 4.6, 4.3) demonstrated anti-proliferative effects on cancer cells.
  • TrkB-IgL 5.11 and 4.11 mAbs significantly suppressed TrkB-mediated signaling pathways.
  • TrkB-IgL 5.11 mAb dose-dependently inhibited TrkB phosphorylation, Akt, and ERK, while inducing Caspase-3 and Caspase-9 activity.

Conclusions:

  • The TrkB-IgL 5.11 antibody effectively inhibits cancer cell proliferation and induces apoptosis by suppressing key signaling pathways.
  • This antibody is a promising therapeutic candidate for cancers overexpressing TrkB.
  • The TrkB-IgL 5.11 antibody is suitable for humanization and potential clinical application in cancer treatment.